On September 13, 2021 IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, reported that the first peer reviewed article "Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral Breast Tumor Recurrence in the ICE3 Trial" was published in the Annals of Surgical Oncology with Dr. Richard Fine, MD, FACS, an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown, TN, as the lead author (Press release, IceCure Medical, SEP 13, 2021, View Source [SID1234587654]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Having a peer reviewed publication of the ICE3 Clinical Study[1] interim results in a well-respected medical journal represents a major milestone for IceCure in solidifying the efficacy and adaptation of its minimally invasive solution by the broader medical community for the treatment of certain breast cancers," stated IceCure CEO, Eyal Shamir. The article reports the results previously announced on April 29, 2021 at the American Society of Breast Surgeons Annual Meeting, that at a mean of 34.83 months following treatment with ProSense Cryoablation System, only 2.06% (4 of 194 patients) experienced cancer recurrence.
The journal article concludes that "breast cryoablation presents a promising alternative to surgery while offering the benefits of a minimally-invasive procedure with minimal risks."[2] Study author Dr. Fine stated that "the 3-year ICE3 trial results highlighting the efficacy and safety of the procedure in this patient group are extremely promising for breast cryoablation. Being able to provide a minimally-invasive option for treating appropriate low risk patients represents a dramatic improvement in care – the procedure is quick, painless and can be delivered with local anesthesia in doctor’s office, with minimal recovery time and excellent cosmetic outcomes."
Dr. Richard Fine will be presenting his findings on cryoablation at the upcoming Mayo Clinic School of Continuous Professional Development Conference "Breast Cancer Care: Innovation, Disruptive Technologies and Early Adopters 2021" in Rochester, MN on Friday, September 17, 2021. Scott Peairs, IceCure US Commericial Director, will be on site at the exhibit.